ArticleJapanese journal of radiology2025
Incremental value of extracellular volume fraction based on CT for microsatellite status in colorectal cancer.
Article in Japanese journal of radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The value of extracellular volume based on spectral CT in lymph node metastasis, perineural invasion, and lymphovascular invasion of colon cancer.Abdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThis study aimed to establish and validate a predictive model for microsatellite instability (MSI) in colorectal cancer (CRC) patients by integrating CT-based extracellular volume (ECV) fraction, clinical parameters, and conventional imaging signs.
methodsA retrospective cohort of CRC patients was divided into a training set (n = 155) and a validation set (n = 67). The ECV fraction was derived by incorporating patients' hematocrit values and applying subtraction algorithms to pre-contrast and equilibrium phase images. The ECV fraction was then combined with clinical parameters and conventional imaging signs to construct two predictive models: a clinical imaging sign model and a hybrid model. Model performance was assessed using the area under the curve (AUC), net reclassification index (NRI), and integrated discrimination improvement (IDI).
resultsIn both sets, the clinical imaging sign model demonstrated robust MSI prediction, with AUCs of 0.829 (training) and 0.792 (validation). Incorporating ECV fraction showed superior performance with corresponding AUCs of 0.867 and 0.848. Significant improvements in both NRI and IDI were observed when comparing the hybrid model to the clinical imaging sign model.
conclusionThe combination of ECV fraction, clinical parameters, and conventional imaging signs of tumor lesions, when analyzed using logistic regression, enables accurate prediction of MSI status in CRC. This approach demonstrates the incremental predictive value contributed by ECV fraction in MSI assessment.
Indexed as
Identifiers
40613851What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.